[Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Holger Wallmeier, Kirsten Völp, Gregor Schulz] DE Dietzenbach Provided are methods of screening to identify molecules capable of binding to CD4 and capable of activating CD4+CD25+ regulatory T cells. Further provided are antibodies and antibody fragments capable of activating CD4+CD25+ regulatory T cells and methods and uses involving the antibodies and fragments thereof.

[VEELKEN, Hendrik, OSTERROTH, Frank] Hugstetter Strasse 49 79106 Freiburg;Karlstrasse 48 79104 Freiburg;Eschholzstrasse 16 79106 Freiburg The present invention relates to methods for isolating DNA encoding immunoglobulin V-regions, methods for determining the idiotype of B cell lymphomas, methods for the preparation of idiotypic Fab fragments, Fab fragments produced by such methods and vaccines containing such Fabs. The invention also concerns methods for the stimulation of T cells. The invention further concerns the uses of anchored PCR in those methods.

[Matthias Germer, Frank Osterroth, Silke Aigner, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken] DE Langen The present invention provides a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject in a dose of the agent from 10 mg to 200 mg.

[OSTERROTH, Michael, MERKEL, Frank, ELSINGER, Bernd] Flehinger Strasse 59 75038 Oberderdingen;Jurastrasse 27 68753 Waghäusel;Wiesenäckerstrasse 26 71254 Ditzingen;Hägenichstrasse 17 75056 Sulzfeld The invention relates to a mounting device (138) for mounting fitted equipment, in particular a fitted sink (100) to a worktop (122). Said device comprises at least one mounting element (132) on the fitted equipment, at least one mounting element (134) on the worktop and at least one tensioning element (136) for tensioning the worktop mounting element (134) and the mounting element (132) on the fitted equipment in relation to one another, the tensioning element (136) having a threaded section (154), a mounting section (158) and a section with a narrow diameter (156) situated between the threaded section (154) and the mounting section (158), whose diameter (d) is less than the diameter (D) of the mounting section (158). The mounting (132) element on the fitted equipment has at least one passage (150), through which the section with a narrow diameter (156) of the tensioning element (136) extends, when the mounting device (138) is assembled. The aim of the invention is to provide a mounting device that permits the fitted equipment to be reliably mounted on the worktop (122) and does not detrimentally affect the appearance of said equipment. To achieve this, the mounting element (132) on the fitted equipment has a fixing region (140), by means of which the mounting element (132) on the fitted equipment rests against an edge region (102) of said equipment, when the mounting device (138) is assembled.

[AIGNER, Silke, GERMER, Matthias, OSTERROTH, Frank, UHEREK, Christoph, KRAUS, Elmar, WARTENBERG-DEMAND, Andrea, WOLF, Daniele, KAISER, Sibylle, LINDNER, Juergen, BRUECHER, Christoph, DAELKEN, Benjamin] Landsteinerstrasse 5 63303 Dreieich;An der kurzen Gewanne 24 67227 Frankenthal;Theodor-Heuss-Strasse 1 63225 Langen;Konrad-Adenauer-Allee 22 63128 Dietzenbach;Lachenwoerthsweg 6 63500 Seligenstadt;Bahnhofstrasse 51 A 61118 Bad Vilbel;Waldstrasse 68 35440 Linden;Zum Roehrbrunnen 17a 63303 Dreieich;Stuckertstrasse 3 64673 Zwingenberg;Sandplackenstrasse 5 60488 Frankfurt;Unter den Tannen 3a 65760 Eschborn;Eleonore-Sterling-Strasse 40 60433 Frankfurt am Main The provision of a pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.

[Silke Aigner, Matthias Germer, Frank Osterroth, Christoph Uherek, Elmar Kraus, Andrea Wartenberg-Demand, Daniele Wolf, Sibylle Kaiser, Juergen Lindner, Christoph Bruecher, Benjamin Daelken, Gregor Schulz] DE Frankenthal The present invention provides pharmaceutical composition for treating an autoimmune disease comprising a pharmaceutically acceptable carrier and an agent capable of activating CD4+CD25+ regulatory T cells, wherein the composition is to be administered to a subject at most every 3 days.

[OSTERROTH, Frank, UHEREK, Christoph, BRUECHER, Christoph, DAELKEN, Benjamin, ENGLING, André, HAEDER, Thomas, WARTENBERG-DEMAND, Andrea, NIEMANN, Gabriele, ZUBER, Chantal, CZELOTH, Niklas, AIGNER, Silke, ZENG, Steffen, SCHULZ, Gregor] Landsteinerstrasse 5 63303 Dreiech;830 Winter Street Waltham, Massachusetts 02451;Konrad-Adenauer-Allee 22 63128 Dietzenbach;Lachenwoerthsweg 6 63500 Seligenstadt;Unter den Tannen 3a 65760 Eschborn;Eleonore-Sterling-Strasse 40 60433 Frankfurt am Main;Schweinfurter Weg 84 60599 Frankfurt;Koenigsbergerstrasse 4 63303 Dreieichenhain;Waldstrasse 68 35440 Linden;Bergwaldstrasse 4 76227 Karlsruhe;Schwarzwaldstrasse 15 60528 Frankfurt;Pappelweg 9 63303 Dreieich;An der kurzen Gewanne 24 67227 Frankenthal;Albert Einstein Str. 13 64839 Münster;Rosenstrasse 13 79224 Umkirch Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.

[Elmar Kraus, Christoph Bruecher, Benjamin Daelken, Steffen Zeng, Frank Osterroth, Christoph Uherek, Silke Aigner, Matthias Germer] DE Bad Vilbel Disclosed are immunoconjugates having in particular specificity for CD138 expressed on target cells and which display homogenous targeting. The immunoconjugates may be sterially hindered and/or contain a cleavable linker.

[KRAUS, Elmar, BRUECHER, Christoph, DAELKEN, Benjamin, GERMER, Matthias, ZENG, Steffen, OSTERROTH, Frank, UHEREK, Christoph, AIGNER, Silke] Landsteinerstrasse 5 63303 Dreieich;Bahnhofstrasse 51 A 61118 Bad Vilbel;Unter den Tannen 3a 65760 Eschborn;Eleonore-Sterling-Strasse 40 60433 Frankfurt am Main;Theodor-Heuss-Strasse 1 63225 Langen;Albert Einstein Strasse 13 64839 Muenster;Konrad-Adenauer-Allee 22 63128 Dietzenbach;Lachenwoerthsweg 6 63500 Seligenstadt;An der kurzen Gewanne 24 67227 Frankenthal Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.

[Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng] DE Dietzenbach Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.